Atomo Diagnostics (ASX:AT1) said its strategic partner Lumos Diagnostics (ASX:LDX) placed an order with the company for the supply of $410,000 worth of Pascal cassettes to support scaling up the demand for the company's diagnostic product, FebriDx, in the US market, according to a Thursday Australian bourse filing.

The company said that Lumos indicated that it expects the agreement with Phase to generate FebriDx product sales of up to $316 million over six years, assuming that the clinical laboratory improvement amendments (CLIA) waiver is granted and contracted minimum order quantities are achieved.

The FebriDx test secured a 510k clearance from the US Food and Drug Administration and is currently well progressed through a CLIA waiver study that is expected to be completed this month.

Atomo Diagnostics' shares fell 5% in recent Thursday trade. Lumos Diagnostics' shares jumped almost 6%, earlier hitting their highest since September 2023.